Shoreline Biosciences Announces $ 43 Million Funding to Advance Pipeline of Natural Killer Allogeneic Cellular Immunotherapies and Macrophages Derived from Pluripotent Stem Cells

0

SAN DIEGO, April 7, 2021 / PRNewswire / – Shoreline Biosciences, Inc. (Shoreline) and other critical illnesses, today announced the completion of a $ 43 million increase in capital. Funding was led by Boxer Capital, with participation from BVF Partners LP, Commodore Capital, Cormorant Capital, Janus Henderson Investors, Logos Capital, Kite, a Gilead company, and Wedbush Healthcare Partners, in addition to Stork Capital and others investors. As part of the funding, Christophe Fuglesang, Ph.D., JD of Boxer Capital, has joined the board of directors of Shoreline.

Proceeds from the funding will enable Shoreline to accelerate the advancement of its proprietary iPSC platform focused on the development of next-generation NK cell and macrophage cell therapies, while supporting research efforts to create Potent and persistent NK cell specific chimeric antigen receptors (CARs). , switchable CAR-NK cell engageers, and macrophage-specific CARs. In addition, Shoreline has forged a strategic relationship with UC San Diego’s Advanced Cell Therapy Lab, a well-known manufacturing partner, to ensure GMP manufacturing of Shoreline’s cell therapy products.

“We are delighted to have the support of such exceptional investors who share our vision and commitment to build a differentiated and exciting cell therapy business with the ambition to lead the next wave of allogeneic, autonomous, targeted and standardized cell therapy. , ” noted Kleanthis G. Xanthopoulos, Ph.D., Co-Founder and Executive Chairman of Shoreline. “With this funding, we are well positioned to bring our programs to the clinic in multiple indications and to build a domain-dominant cell therapy company.”

“We are looking to invest in companies that are pushing the boundaries of scientific innovation and Shoreline is doing just that. Their approach to intelligently designing iPSC-derived cell therapies will help solve many of the current challenges in cell therapy,” said declared Christophe Fuglesang, Ph.D., JD, co-founder and CEO of Boxer Capital.

Shoreline Biosciences was co-founded by a renowned expert in cell therapy Dan Kaufman, MD, Ph.D. and biotechnology veterans Steven holtzman, William sandborn, MD and Kleanthis G. Xanthopoulos, Ph.D.

About Shoreline Biosciences

Shoreline is a biotechnology company dedicated to advancing the development of ready-to-use, targeted and standardized allogeneic cellular immunotherapies intelligently designed for cancer and other serious diseases. Shoreline is building a pipeline of natural killer cell (NK) and macrophage cell therapy candidates derived from its deep expertise in iPSC differentiation methods and genetic reprogramming of disease-relevant pathways. Shoreline has a strategic manufacturing relationship with the Advanced Cell Therapy Lab and is backed by high quality institutional investors including Boxer Capital, BVF Partners LP, Commodore Capital, Cormorant Capital, Janus Henderson Investors, Logos Capital, Kite, a company Gilead, Wedbush Healthcare Partners, Stork Capital and others. Shoreline Biosciences is headquartered at San Diego, California.

For more information, please visit https://shorelinebio.com/ and engage with us on LinkedIn.

Shoreline Biosciences Investor and Media Contact:

Amy conrad
Juniper hint
[email protected]
858-366-3243

[email protected]
858-997-2703

Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/shoreline-biosciences-announces-43m-financing-to-advance-pipeline-of-allogeneic-natural-killer-and-macrophage -cellular -immunotherapies-derived-from-pluripotent-stem-cells-301263611.html

SOURCE Shoreline Biosciences, Inc.

Leave A Reply

Your email address will not be published.